Enveric Biosciences, Inc.
ENVB
Last
$1.45
Day
-4.0%
1y
-82.0%
5y
-100.0%
52w
-88.5%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1333d
EMA 21
1.49
EMA 50
1.51
EMA 200
4.64
20d high
-7.8%
5y high
-100.0%
5y range
0th
Positions held
Your positionsENVB isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-16
Hold
avoid
Signal
Strong Sell
Target
$1.67
Stop
$1.40
Stop distance
3.5%
Target vs last
+15.2%
Fundamentals
| Market cap | $6.80M | Enterprise value | -$1.49M | Trailing P/E | — | Forward P/E | -1.08 |
| PEG | — | Price / book | 0.74 | Beta | 1.18 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -1.7% | ROA | -87.3% | Debt / equity | — |
| Current ratio | 10.21 | Free cash flow | -$5.20M | Analyst recommendation | none | Mean target | — |
| 52w high | $13.25 | 52w low | $1.17 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$3.0M | -$1.6M | -$2.2M | -$1.9M | -$2.5M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$3.0M | -$1.6M | -$2.2M | -$1.9M | -$2.5M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$8.8M | -$9.6M | -$17.3M | -$18.5M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | $0.0M |
| Operating income | -$8.8M | -$9.6M | -$18.3M | -$20.0M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-01 · Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
2026-08-14 · Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
2026-08-05 · Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
2026-07-28 · Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
Price (daily)
Full chart · RSI · MACD · patternsENVB · daily-1.3% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin